Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Listening to generic Prozac: winners, losers, and sideliners.

Druss BG, Marcus SC, Olfson M, Pincus HA.

Health Aff (Millwood). 2004 Sep-Oct;23(5):210-6.

PMID:
15371387
2.

Prozac. A bitter pill.

McLean B.

Fortune. 2001 Aug 13;144(3):118-22, 126, 130-2. No abstract available.

PMID:
11499050
3.

Lilly goes off Prozac.

Simons J.

Fortune. 2004 Jun 28;149(13):179-80, 182, 184. No abstract available.

PMID:
15241951
4.

State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.

Kelton CM, Chang LV, Kreling DH.

Health Aff (Millwood). 2013 Jul;32(7):1204-11. doi: 10.1377/hlthaff.2013.0161.

PMID:
23836735
5.

Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.

McManus P, Birkett DJ, Dudley J, Stevens A.

Pharmacoepidemiol Drug Saf. 2001 Jun-Jul;10(4):295-300.

PMID:
11760489
6.

Undocumented source of pharmacy benefit manager revenue.

Siracuse MV, Clark BE, Garis RI.

Am J Health Syst Pharm. 2008 Mar 15;65(6):552-7. doi: 10.2146/ajhp070389.

PMID:
18319501
7.

Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.

Haas JS, Phillips KA, Gerstenberger EP, Seger AC.

Ann Intern Med. 2005 Jun 7;142(11):891-7.

PMID:
15941695
8.

Effect of generic-only drug benefits on seniors' medication use and financial burden.

Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM.

Am J Manag Care. 2006 Sep;12(9):525-32.

9.

The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Panattoni LE.

J Health Econ. 2011 Jan;30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8.

PMID:
21074873
10.

The unlicensed lives of antidepressants in India: generic drugs, unqualified practitioners, and floating prescriptions.

Ecks S, Basu S.

Transcult Psychiatry. 2009 Mar;46(1):86-106. doi: 10.1177/1363461509102289.

PMID:
19293281
11.

Summaries for patients. Potential savings with substitution of generic drugs for brand-name drugs.

[No authors listed]

Ann Intern Med. 2005 Jun 7;142(11):I30. No abstract available.

PMID:
15941691
12.

Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.

Sava FA, Yates BT, Lupu V, Szentagotai A, David D.

J Clin Psychol. 2009 Jan;65(1):36-52. doi: 10.1002/jclp.20550.

PMID:
19051275
13.

Brand-name versus generic.

Copeland KR, Boccuzzi SJ.

Health Aff (Millwood). 2007 Jul-Aug;26(4):1198-9; author reply 1199. No abstract available.

PMID:
17630468
14.

Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.

Boersma C, Klok RM, Bos JM, Naunton M, van den Berg PB, de Jong-van den Berg LT, Postma MJ.

Appl Health Econ Health Policy. 2005;4(3):191-6.

PMID:
16309337
15.
16.

The impact of generic goods in the pharmaceutical industry.

Ferrándiz JM.

Health Econ. 1999 Nov;8(7):599-612.

PMID:
10544326
17.

The career of a celebrity pill. As Prozac's long reign comes to an end, experts are questioning its legacy.

Szegedy-Maszak M.

US News World Rep. 2001 Aug 6;131(5):38-9. No abstract available.

PMID:
11499369
18.

The spread: pilot study of an undocumented source of pharmacy benefit manager revenue.

Garis RI, Clark BE.

J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):15-21.

PMID:
14965148
19.

The generics in transplantation and the rules on their use.

Masri M.

Exp Clin Transplant. 2003 Jun;1(1):65-8.

20.

Study: U.S. generic drugs cost less then Canadian drugs.

Bren L.

FDA Consum. 2004 Jul-Aug;38(4):9.

Supplemental Content

Support Center